WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001023391) TRIAZOLOPURINE DERIVATIVES, DRUG COMPOSITIONS CONTAINING THE SAME AND ADENOSINE A3 RECEPTOR AFFINITIVE AGENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/023391    International Application No.:    PCT/JP2000/006487
Publication Date: 05.04.2001 International Filing Date: 22.09.2000
Chapter 2 Demand Filed:    26.02.2001    
IPC:
C07D 487/14 (2006.01)
Applicants: OTSUKA PHARMACEUTICAL FACTORY, INC. [JP/JP]; 115, Aza Kuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima 772-8601 (JP) (For All Designated States Except US).
OKAMURA, Takashi [JP/JP]; (JP) (For US Only).
KUROGI, Yasuhisa [JP/JP]; (JP) (For US Only).
NISHIKAWA, Hiroshi [JP/JP]; (JP) (For US Only)
Inventors: OKAMURA, Takashi; (JP).
KUROGI, Yasuhisa; (JP).
NISHIKAWA, Hiroshi; (JP)
Agent: FUKAI, Toshikazu; Treemont Hoei Building, 3-4, Funakoshi-cho 1-chome, Chuo-ku, Osaka-shi, Osaka 540-0036 (JP)
Priority Data:
11/275270 28.09.1999 JP
2000/157655 29.05.2000 JP
Title (EN) TRIAZOLOPURINE DERIVATIVES, DRUG COMPOSITIONS CONTAINING THE SAME AND ADENOSINE A3 RECEPTOR AFFINITIVE AGENTS
(FR) DERIVES DE TRIAZOLOPURINE, COMPOSITIONS MEDICAMENTEUSES LES CONTENANT ET AGENT A AFFINITE POUR LE RECEPTEUR DE L'ADENOSINE A3
Abstract: front page image
(EN)Triazolopurine derivatives represented by general formula (1) exhibit affinity for adenosine A3 receptor and are therefore useful as the ingredient of drug compositions wherein R?1¿ and R?2¿ are each as defined in the description.
(FR)La présente invention concerne des dérivés de triazolopurine représentés par la formule générale (I) dans laquelle R?1¿ et R?2¿ sont tels que définis dans la description. Ces dérivés, qui présentent de l'affinité pour le récepteur de l'adénosine A3, conviennent comme ingrédients de compositions médicamenteuses.
Designated States: AU, CA, CN, JP, KR, US.
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)